ESR1 and breast carcinoma: Both ER and PR must be tested on each primary breast carcinoma and should be re-assessed on any recurring/metastatic lesions if tissue is available for testing, as differences in expression profile can occur in up to 50% of cases [10, 12, 43, 44].